新闻

NEW YORK-- Wall Street's three major indexes fell on Monday as investors waited for quarterly reports from large retailers to provide insights into U.S. consumer spending, while oil prices rose as the U.S. and Iran appeared no closer to a deal. Oil futures settled up more than $2 per barrel as investor pessimism about diplomatic efforts to resolve the Iran war fanned global supply worries. The gain in oil provided support for the energy index .SPNY. Investors, with July's weak retail sales and jobs data fresh in their minds, were cautious as they waited for quarterly results from retailers. Home improvement company Home Depot HD.Nis due to report on Tuesday, and retail bellwether Walmart WMT.O on Thursday. "Concerns about recent softer data have the market being a bit tepid and waiting for retail earnings for direction," said Phil Blancato, chief market strategist at Osaic Wealth, who added that volume is often weak in August, when many traders take vacations. "There's a combination of summer doldrums and waiting for data on the consumer." According to preliminary data, the S&P 500 .SPX lost 39.55 points, or 0.51%, to end at 7,746.21 points, while the Nasdaq Composite .IXIC lost 76.87 points, or 0.31%, to 26,652.29. The Dow Jones Industrial Average .DJI fell 263.21 points, or 0.49%, to 53,469.20. Most of the benchmark S&P 500's 11 major industry sectors lost ground on the day with communications services .SPLRCL, consumer staples .SPLRCS and consumer discretionary .SPLRCD among the weakest. The S&P 500 technology sector .SPLRCT flitted between red and green during the session. Trading in technology has been volatile with investors anxious about whether hefty spending on artificial intelligence will pay off. Reuters reported on Friday that two people familiar with Anthropic's financials said the company, which is preparing for its IPO, forecast 2028 revenue of roughly $190 billion to $200 billion. On Monday, gains in chip stocks were offset by declines in software with the PHLX semiconductor index .SOX rallying while the S&P 500 Software & Services index .SPLRCISsank. Investors are also waiting for results, due out next week, from leading AI chipmaker Nvidia NVDA.O, the world's most valuable company. In individual movers, U.S.-listed shares of Vista VISTAA.MX, VIST.N gained ground after Peter Thiel bought a 1% stake in the Latin American oil company.

"At this point, saying that AI will cure cancer is more a cliche than it is inspiring, and most people think it is deceptive. The thing that will work is *actually curing cancer*. I think by far the most accurate criticism of AI companies including Anthropic is that we haven't yet delivered on our big promises to benefit the world." - Dario Amodei - Anthropic CEO The central problem is not whether artificial intelligence can one day produce dramatic medical breakthroughs, but whether a technology industry can keep asking for trust before it has earned it. The tension is between grand claims and visible delivery: promises about curing disease, transforming science, and improving human welfare are easy to make, yet they quickly lose force when the public sees mainly product launches, market hype, and warnings about risk. That gap matters because credibility in frontier technology is cumulative, and once it erodes, even sincere claims begin to sound like salesmanship . That is the background to Dario Amodei's position as Anthropic's chief executive. In the attached source, he argues that the public has become sceptical not because leaders talk too much about danger, but because the industry has not yet produced enough undeniable benefits. He also makes a sharper point: saying that AI will cure cancer has already become a cliche, and cliches do not persuade people who suspect they are being manipulated. The more persuasive test is not rhetorical ambition but actual therapeutic progress, because tangible success changes the terms of the debate in a way no slogan can . The logic here is pragmatic rather than defensive. Amodei is not rejecting the aspiration that AI could reshape biology; in the same source he says he believes the technology could help cure most human disease within 5 to 10 years, and he links that belief to concrete work on biology, medicine, and regulatory streamlining . The deeper point is that future-facing industries are judged less by their stated intentions than by whether they convert capability into public value. A company can announce a transformative mission, but if ordinary people cannot see the output, they will treat the mission as branding. That is why the issue is not simply messaging. It is the credibility deficit created when talk outruns proof . Trust, delivery, and the politics of evidence Amodei's claim is also a critique of the broader tech cycle. Many companies now rely on a familiar sequence: announce a world-changing objective, describe the scale of the opportunity, and then ask critics to wait for the long arc of innovation to deliver results. In sectors such as consumer software, that pattern can work because benefits arrive quickly and individually. In AI, especially in medicine, the public asks for stronger evidence because the stakes are higher and the promised gains are more consequential. If a system is said to revolutionise cancer care, people do not want an ever-receding vision. They want a trial, a therapy, a measurable improvement, and a reason to believe the claim is more than aspiration . The source also shows why this issue is linked to regulation rather than standing apart from it. Amodei argues that objective institutional processes can decentralise power, and he presents regulation not as a simplistic route to capture, but as a possible discipline on frontier labs that still leaves room for open-weights models and smaller competitors . That matters because public trust is not only emotional. It is institutional. When people see rules applied unevenly, or see powerful firms exempt themselves from scrutiny, they infer that promised benefits may never arrive for them. By contrast, a system that tests the most powerful models more rigorously than smaller ones can signal that the goal is safety and accountability, not cartel protection . There is also a strategic reason the medical promise sounds less convincing today than it did a few years ago. The industry has spent a long time describing AI in terms of scale, speed, and generality, while the public has mostly experienced it through chatbots, workplace tools, and content systems that feel impressive but not existentially beneficial. That creates a perception problem. If the technology is supposed to accelerate drug discovery, diagnose disease, or improve clinical workflow, then visible proof has to show up in those domains before the public will accept the larger narrative. Without that proof, any claim about curing cancer sounds detached from reality, even if the underlying research programme is serious . Why the public reads optimism as manipulation Amodei's most pointed line is that people now think the promise is deceptive. That reaction is rooted in a wider cultural memory of industries that overstated social benefit while externalising costs. In that climate, a polished campaign about AI saving lives can sound less like a commitment and more like a reputational shield. The irony is that overstatement can weaken the very cause it is meant to advance. If leaders promise too much too early, they raise the burden of proof beyond what current systems can meet, and each unmet forecast then hardens scepticism further . His preferred answer is not to soften the ambition but to earn the right to speak ambitiously. In the source, he says Anthropic is increasing its work in biology and medicine, hopes for strong results in the coming years, and expects early signs in the coming months . That is a significant shift in emphasis from abstract possibility to operational pipeline. It suggests that the industry's legitimacy will depend on whether frontier labs can produce visible wins in high-impact fields, not merely on whether they can publish long research essays or give polished interviews. In other words, the path back to trust runs through evidence generation, not narrative management . That also explains why Amodei resists the idea that more positive messaging would solve the problem. A marketing campaign can amplify attention, but it cannot substitute for competence or delivery. Once the public decides that a claim sounds rehearsed, more enthusiasm often backfires. His argument is that honesty about risk is compatible with optimism about benefit, but optimism must remain tethered to demonstrated progress. Otherwise, the industry risks reinforcing the very cynicism it wants to dissolve . Seen this way, the statement is less about one company than about a maturation test for the whole AI sector. The next phase is not simply making models larger or interfaces smoother. It is translating frontier capability into socially legible gains that survive public scrutiny, regulatory oversight, and clinical validation. Until that happens, the phrase about curing cancer will keep sounding premature, not because the research agenda is meaningless, but because the public has learned to separate possibility from proof. The companies that close that gap will shape the reputation of AI far more decisively than any slogan ever could . References 1. "X Post - Dario AModei" - https://x.com/DarioAmodei/status/2088758819304443967